Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

EFFECTIVENESS AND SAFETY OF SOTAGLIFLOZIN IN SLOWING KIDNEY FUNCTION DECLINE IN PERSONS WITH TYPE 1 DIABETES AND MODERATE TO SEVERE DIABETIC KIDNEY DISEASE

Intervention/treatment:
SOTAGLIFLOZIN
Medical condition:
TYPE 1 DIABETES
Protocol code:
SUGARNSALT2023
Control number:
285368
Status:
Recruiting
Approved:
May 02, 2024
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT06217302
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 75 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Christine Mendonca
Role
CONTACT
Phone:
617-334-2257
Name
Alexis Puthussery
Role
CONTACT
Phone:
617-975-8235
Sponsor
DR ALESSANDRO DORIA

Locations

Alberta

Alberta Diabetes Institute
Edmonton, Alberta, T6G 2E1
Recruiting
Name
Dominique Forrest
Role
CONTACT
Name
Jyoti Singh
Role
CONTACT
Name
Peter Senior, MD
Role
PRINCIPAL_INVESTIGATOR
Name
Anna Lam, MD
Role
SUB_INVESTIGATOR
Unversity of Calgary
Calgary, Alberta, T2T 5C7
Recruiting
Name
Jenny Schulz
Role
CONTACT
Name
Michelle Smith, RN
Role
CONTACT
Name
Ronald Sigal, MD MPH
Role
PRINCIPAL_INVESTIGATOR

British Columbia

St. Paul's Hospital
Vancouver, British Columbia, V6Z 1Y6
Recruiting
Name
Paula Macleod
Role
CONTACT
Name
Adeera Levin, MD
Role
PRINCIPAL_INVESTIGATOR
Name
Sean Barbour, MD
Role
SUB_INVESTIGATOR

Ontario

LMC Diabetes and Endocrinology
Toronto, Ontario, M4G 3E8
Recruiting
Name
Lydia Beaudette
Role
CONTACT
Name
Arlene Vinas
Role
CONTACT
Name
Ronnie Aronson, MD
Role
PRINCIPAL_INVESTIGATOR
Toronto General Hospital
Toronto, Ontario, M5G 2N2
Recruiting
Name
Vesta Lai, RN
Role
CONTACT
Phone:
416-586-4800
Extension 7625
Name
Cheng Xu
Role
CONTACT
Phone:
416-586-4800
Extension 7187
Name
David Cherney, MD
Role
PRINCIPAL_INVESTIGATOR
Name
Bruce Perkins, MD MPH
Role
SUB_INVESTIGATOR
Name
Vikas S. Sridhar, MD
Role
SUB_INVESTIGATOR
Name
Ayodele Odutayo, MD
Role
SUB_INVESTIGATOR
Name
Huajing Ni, MD
Role
SUB_INVESTIGATOR
Name
Taewon Yi, MD
Role
SUB_INVESTIGATOR

Quebec

Institut de Recherches Cliniques de Montréal
Montreal, Quebec, H2W 1R7
Recruiting
Name
Roxane St Amand
Role
CONTACT
Name
Marie Raffray
Role
CONTACT
Name
Remi Rabasa-Lhoret, MD
Role
PRINCIPAL_INVESTIGATOR
Name
Nadine Taleb, MD
Role
SUB_INVESTIGATOR
Did you find what you were looking for?

Contacts and resources